Literature DB >> 21564086

Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons.

Vu C Dang1, MacDonald J Christie1.   

Abstract

Agonists acting on µ-opioid receptors (MOR) are very effective analgesics but cause tolerance during long-term or repeated exposure. Intensive efforts have been made to find novel opioid agonists that are efficacious analgesics but can elude the signalling events that cause tolerance. µ-Opioid agonists differentially couple to downstream signalling mechanisms. Some agonists, such as enkephalins, D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO), methadone and sufentanyl are efficacious at mediating G-protein and effector coupling, as well as triggering MOR regulatory events that include MOR phosphorylation, β-arrestin binding, receptor endocytosis and recycling. By contrast, morphine and closely related alkaloids can mediate efficacious MOR-effector coupling but poorly trigger receptor regulation. Several models have been proposed to relate differential MOR regulation by different opioids with their propensity to cause tolerance. Most are based on dogma that β-arrestin-2 (βarr-2) binding causes MOR desensitization and/or that MOR endocytosis and recycling are required for receptor resensitization. This review will examine some of these notions in light of recent evidence establishing that MOR dephosphorylation and resensitization do not require endocytosis. Recent evidence from opioid-treated animals also suggests that impaired MOR-effector coupling is driven, at least in part, by enhanced desensitization, as well as impaired resensitization that appears to be βarr-2 dependent. Better understanding of how chronic exposure to opioids alters receptor regulatory mechanisms may facilitate the development of effective analgesics that produce limited tolerance.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21564086      PMCID: PMC3372824          DOI: 10.1111/j.1476-5381.2011.01482.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  103 in total

1.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

2.  G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal.

Authors:  Gregory W Terman; Wenzhen Jin; Young-Pyo Cheong; Janet Lowe; Marc G Caron; Robert J Lefkowitz; Charles Chavkin
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

3.  Two distinct mechanisms mediate acute mu-opioid receptor desensitization in native neurons.

Authors:  Vu C Dang; Ian A Napier; MacDonald J Christie
Journal:  J Neurosci       Date:  2009-03-11       Impact factor: 6.167

4.  Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.

Authors:  Priyanka A Madia; Shveta V Dighe; Sunil Sirohi; Ellen A Walker; Byron C Yoburn
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

5.  Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors.

Authors:  Michael Tanowitz; James N Hislop; Mark von Zastrow
Journal:  J Biol Chem       Date:  2008-10-20       Impact factor: 5.157

6.  Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons.

Authors:  Y Joy Yu; Seksiri Arttamangkul; Christopher J Evans; John T Williams; Mark von Zastrow
Journal:  J Neurosci       Date:  2009-01-07       Impact factor: 6.167

7.  Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization.

Authors:  Ji Chu; Hui Zheng; Yuhan Zhang; Horace H Loh; Ping-Yee Law
Journal:  Cell Signal       Date:  2010-01-05       Impact factor: 4.315

8.  Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine.

Authors:  Christopher P Bailey; Daniel Couch; Elizabeth Johnson; Katie Griffiths; Eamonn Kelly; Graeme Henderson
Journal:  J Neurosci       Date:  2003-11-19       Impact factor: 6.167

9.  Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons.

Authors:  C P Bailey; S Oldfield; J Llorente; C J Caunt; A G Teschemacher; L Roberts; C A McArdle; F L Smith; W L Dewey; E Kelly; G Henderson
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

10.  Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons.

Authors:  C P Bailey; J Llorente; B H Gabra; F L Smith; W L Dewey; E Kelly; G Henderson
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386

View more
  67 in total

1.  Themed section: molecular pharmacology of GPCRs.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Endocytic profiles of δ-opioid receptor ligands determine the duration of rapid but not sustained cAMP responses.

Authors:  Hanieh Bagheri Tudashki; Derek N Robertson; Peter W Schiller; Graciela Pineyro
Journal:  Mol Pharmacol       Date:  2013-10-30       Impact factor: 4.436

3.  Agonist Binding and Desensitization of the μ-Opioid Receptor Is Modulated by Phosphorylation of the C-Terminal Tail Domain.

Authors:  William T Birdsong; Seksiri Arttamangkul; James R Bunzow; John T Williams
Journal:  Mol Pharmacol       Date:  2015-05-01       Impact factor: 4.436

4.  Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism.

Authors:  Caroline A Browne; Rebecca L Erickson; Julie A Blendy; Irwin Lucki
Journal:  Neuropharmacology       Date:  2017-02-07       Impact factor: 5.250

Review 5.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

7.  Thalidomide Promotes Morphine Efficacy and Prevents Morphine-Induced Tolerance in Rats with Diabetic Neuropathy.

Authors:  Jianhui Zhao; Hong Wang; Tieying Song; Yunliang Yang; Kunfeng Gu; Pengyu Ma; Zaiwang Zhang; Limin Shen; Jiabao Liu; Wenli Wang
Journal:  Neurochem Res       Date:  2016-08-30       Impact factor: 3.996

8.  NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice.

Authors:  T Doyle; E Esposito; L Bryant; S Cuzzocrea; D Salvemini
Journal:  Neuroscience       Date:  2013-02-27       Impact factor: 3.590

9.  Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure.

Authors:  William T Birdsong; Seksiri Arttamangkul; Mary J Clark; Kejun Cheng; Kenner C Rice; John R Traynor; John T Williams
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

10.  Effect of Sinomenine on the Morphine-Dependence and Related Neural Mechanisms in Mice.

Authors:  Miao Fang; Junkui Li; Daoqi Zhu; Chaohua Luo; Chan Li; Chen Zhu; Menglin Fan; Ken Kin-Lam Yung; Zhixian Mo
Journal:  Neurochem Res       Date:  2017-11-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.